Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Bioorg Med Chem ; 9(7): 1871-7, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11425589

ABSTRACT

An efficient approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one (J-113397) 1, the first non-peptide ORL-1 receptor antagonist described in literature, is outlined. After construction of the piperidine framework through Dieckmann cyclization of the Michael adduct 8 of cyclooctylmethylamine to methyl acrylate, condensation with o-phenylendiamine produced the beta-enamino ester 2, which has been conveniently used to construct the benzimidazolone substituent at C-4. Catalytic hydrogenation of intermediate 11 followed by base-promoted cis--trans isomerization of the key compound 12 led to the formation of ester 13, which was converted to the racemic title compound by LiAlH(4) reduction. The pure enantiomers were obtained by chiral preparative HPLC separation using a derivatized cellulose-based stationary phase.


Subject(s)
Benzimidazoles/chemical synthesis , Benzimidazoles/pharmacology , Narcotic Antagonists/chemical synthesis , Narcotic Antagonists/pharmacology , Piperidines/chemical synthesis , Piperidines/pharmacology , Chromatography, High Pressure Liquid , Receptors, Opioid , Spectrum Analysis , Nociceptin Receptor
2.
J Med Chem ; 44(11): 1675-89, 2001 May 24.
Article in English | MEDLINE | ID: mdl-11356103

ABSTRACT

A stepwise chemical modification from human neurokinin-3 receptor (hNK-3R)-selective antagonists to potent and combined hNK-3R and hNK-2R antagonists using the same 2-phenylquinoline template is described. Docking studies with 3-D models of the hNK-3 and hNK-2 receptors were used to drive the chemical design and speed up the identification of potent and combined antagonsits at both receptors. (S)-(+)-N-(1-Cyclohexylethyl)-3-[(4-morpholin-4-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (compound 25, SB-400238: hNK-3R binding affinity, K(i) = 0.8 nM; hNK-2R binding affinity, K(i) = 0.8 nM) emerged as the best example in this approach. Further studies led to the identification of (S)-(+)-N-(1,2,2-trimethylpropyl)-3-[(4-piperidin-1-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (compound 28, SB-414240: hNK-3R binding affinity, K(i) = 193 nM; hNK-2R binding affinity, K(i) = 1.0 nM) as the first hNK-2R-selective antagonist belonging to the 2-phenylquinoline chemical class. Since some members of this chemical series showed a significant binding affinity for the human mu-opioid receptor (hMOR), docking studies were also conducted on a 3-D model of the hMOR, resulting in the identification of a viable chemical strategy to avoid any significant micro-opioid component. Compounds 25 and 28 are therefore suitable pharmacological tools in the tachykinin area to elucidate further the pathophysiological role of NK-3 and NK-2 receptors and the therapeutic potential of selective NK-2 (28) or combined NK-3 and NK-2 (25) receptor antagonists.


Subject(s)
Morpholines/chemical synthesis , Piperidines/chemical synthesis , Quinolines/chemical synthesis , Receptors, Neurokinin-2/antagonists & inhibitors , Receptors, Neurokinin-3/antagonists & inhibitors , Amino Acid Sequence , Animals , CHO Cells , Cloning, Molecular , Cricetinae , Humans , Models, Molecular , Molecular Sequence Data , Morpholines/chemistry , Morpholines/metabolism , Piperidines/chemistry , Piperidines/metabolism , Quinolines/chemistry , Quinolines/metabolism , Radioligand Assay , Receptors, Neurokinin-2/chemistry , Receptors, Neurokinin-2/metabolism , Receptors, Neurokinin-3/chemistry , Receptors, Neurokinin-3/metabolism , Receptors, Opioid, mu/chemistry , Receptors, Opioid, mu/metabolism , Structure-Activity Relationship
3.
Farmaco ; 56(1-2): 117-9, 2001.
Article in English | MEDLINE | ID: mdl-11347951

ABSTRACT

In the last decade a number of selective and potent non-peptidic agents became available to explore the usefulness of the delta-opioid receptor in modulation of pain of different origins. As a continuing effort in this field, potent and selective delta-opioid agonists based on the pyrrolomorphinan framework have been designed, synthesised and characterised biologically in our laboratories. In animal models, a selected compound of interest, SB 235863, has proved the concept that selective delta-opioid agonists may have great potential as pain relief agents in inflammatory and neuropathic pain conditions. Importantly, such a compound was free of the unwanted side effects usually associated with narcotic analgesics such as morphine.


Subject(s)
Analgesics, Opioid/pharmacology , Receptors, Opioid, delta/agonists , Animals , Drug Design , Humans , Inflammation/drug therapy , Pain/drug therapy , Structure-Activity Relationship
4.
Eur J Pharmacol ; 413(2-3): 143-50, 2001 Feb 16.
Article in English | MEDLINE | ID: mdl-11226387

ABSTRACT

Starting with a partial sequence from Genbank, polymerase chain reaction (PCR) was utilized to isolate the full-length cDNA for NK(3) receptor from mouse brain. The murine NK(3) receptor has a predicted sequence of 452 amino acids, sharing 96% and 86% identity to the rat and human NK(3) receptors, respectively. Binding affinities and functional potencies of tachykinin receptor agonists were similar in HEK (human embryonic kidney) 293 cells expressing murine NK(3) receptor and human NK(3) receptor, although substance P and neurokinin A were more potent stimulators of Ca(2+) mobilization in murine NK(3) receptor cells. NK(3) receptor-selective antagonists from two structural classes, had 10- to 100-fold lower binding affinities for murine NK(3) receptor compared to human NK(3) receptor, and about 5- to 10-fold reduced potency in the murine NK(3) receptor functional assay. The results demonstrate species differences in the potencies of tachykinin receptor antagonists in murine and human NK(3) receptors, and the lower potencies in the former should be taken into consideration when using murine disease models.


Subject(s)
Calcium/metabolism , Receptors, Neurokinin-3/physiology , Amino Acid Sequence/physiology , Animals , Cloning, Molecular/methods , Humans , Mice , Molecular Sequence Data , Neurokinin A/metabolism , Neurokinin A/pharmacology , Quinolines/chemistry , Quinolines/metabolism , Quinolines/pharmacology , Receptors, Neurokinin-3/drug effects
5.
J Pharmacol Exp Ther ; 295(1): 373-81, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10992004

ABSTRACT

The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-car boxami de], a human NK-3 receptor (hNK-3R) antagonist, was determined. SB-222200 inhibited (125)I-[MePhe(7)]neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a K(i) = 4.4 nM and antagonized NKB-induced Ca(2+) mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC(50) = 18.4 nM. SB-222200 was selective for hNK-3 receptors compared with hNK-1 (K(i) > 100,000 nM) and hNK-2 receptors (K(i) = 250 nM). In HEK 293 cells transiently expressing murine NK-3 receptors (HEK 293-mNK-3R), SB-222200 inhibited binding of (125)I-[MePhe(7)]NKB (K(i) = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC(50) = 265 nM). In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED(50) values of approximately 5 mg/kg. SB-222200 effectively crossed the blood-brain barrier in the mouse and rat. The inhibitory effect of SB-222200 against senktide-induced behavioral responses in the mouse correlated significantly with brain, but not plasma, concentrations of the compound. Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concentrations (C(max) = about 400 ng/ml) and bioavailability of 46%. The preclinical profile of SB-222200, demonstrating high affinity, selectivity, reversibility, oral activity, and central nervous system penetration, suggests that it will be a useful tool compound to define the physiological and pathophysiological roles of NK-3 receptors, in particular in the central nervous system.


Subject(s)
Brain/drug effects , Quinolines/pharmacology , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , Brain/metabolism , CHO Cells , Calcium/metabolism , Cricetinae , Dose-Response Relationship, Drug , Humans , In Vitro Techniques , Iris/drug effects , Iris/physiology , Male , Mice , Mice, Inbred BALB C , Peptide Fragments/pharmacology , Quinolines/pharmacokinetics , Rabbits , Rats , Rats, Sprague-Dawley , Substance P/analogs & derivatives , Substance P/pharmacology
6.
Mol Pharmacol ; 58(3): 552-9, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10953048

ABSTRACT

There have been proposals that the tachykinin receptor classification should be extended to include a novel receptor, the "neurokinin-4" receptor (NK-4R), which has a close homology with the human NK-3 receptor (hNK-3R). We compared the pharmacological and molecular biological characteristics of the hNK-3R and NK-4R. Binding experiments, with (125)I-[MePhe(7)]-NKB binding to HEK 293 cell membranes transiently expressing the hNK-3R (HEK 293-hNK-3R) or NK-4R (HEK 293-NK-4R), and functional studies (Ca(2+) mobilization in the same cells) revealed a similar profile of sensitivity to tachykinin agonists and antagonists for both receptors; i.e., in binding studies with the hNK-3R, MePhe(7)-NKB > NKB > senktide >> NKA = Substance P; with the NK-4R, MePhe(7)-NKB > NKB = senktide >> Substance P = NKA; and with antagonists, SB 223412 = SR 142801 > SB 222200 >> SR 48968 >> CP 99994 for both hNK-3R and NK-4R. Thus, the pharmacology of the two receptors was nearly identical. However, attempts to isolate or identify the NK-4R gene by using various molecular biological techniques were unsuccessful. Procedures, including nested polymerase chain reaction studies, that used products with restriction endonuclease sites specific for either hNK-3R or NK-4R, failed to demonstrate the presence of NK-4R in genomic DNA from human, monkey, mouse, rat, hamster, or guinea pig, and in cDNA libraries from human lung, brain, or heart, whereas the hNK-3R was detectable in the latter libraries. In view of the failure to demonstrate the presence of the putative NK-4R it is thought to be premature to extend the current tachykinin receptor classification.


Subject(s)
Receptors, Neurokinin-3/metabolism , Receptors, Tachykinin/metabolism , Binding, Competitive , Biological Transport , Calcium/metabolism , Cells, Cultured , DNA, Complementary/analysis , Humans , Polymerase Chain Reaction , Radioligand Assay , Receptors, Neurokinin-3/drug effects , Receptors, Neurokinin-3/genetics , Receptors, Tachykinin/drug effects , Receptors, Tachykinin/genetics , Receptors, Tachykinin/isolation & purification , Restriction Mapping , Tachykinins/metabolism
7.
Eur J Med Chem ; 35(3): 275-82, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10785553

ABSTRACT

Anew sequence, which encoded a novel G protein-coupled receptor, was disclosed by two different groups, using the nucleic acid probes based on the delta opioid receptor, first cloned in 1992. The new receptor, which Meunier called opioid-receptor-like 1 (ORL-1), was shown to share high homology with the opioid receptors and therefore thought to be a potential target for new analgesics. In this respect, the present review reports on the literature referring to ORL-1, to its natural ligand (nociceptin or orphanin FQ) and to several synthetic analogues recently described, both as agonists or antagonists at the receptor.


Subject(s)
Analgesics, Opioid/pharmacology , Receptors, Opioid/drug effects , Amino Acid Sequence , Animals , Humans , Molecular Sequence Data , Nociceptin Receptor
8.
Farmaco ; 54(6): 364-74, 1999 Jun 30.
Article in English | MEDLINE | ID: mdl-10443017

ABSTRACT

Results from a medicinal chemistry approach aimed at replacing the quinoline ring system in the potent and selective human neurokinin-3 (hNK-3) receptor antagonists 1-4 of general formula I are discussed. The data give further insight upon the potential NK-3 pharmacophore. In particular, it is highlighted that both the benzene-condensed ring and the quinoline nitrogen are crucial determinants for optimal binding affinity to the hNK-3 receptor. Some novel compounds maintained part of the binding affinity to the receptor (5, 6, 10 and 13) and compound 5, featuring the naphthalene ring system, appears to be suitable for further modifications; it offers the option to introduce electron-withdrawing groups at position 2 and 4, conferring on the ring an overall electron-deficiency similar to that of the quinoline.


Subject(s)
Quinolines/chemical synthesis , Quinolines/pharmacology , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , Binding, Competitive/drug effects , CHO Cells , Cloning, Molecular , Cricetinae , Humans , Radioligand Assay , Structure-Activity Relationship
9.
J Med Chem ; 42(6): 1053-65, 1999 Mar 25.
Article in English | MEDLINE | ID: mdl-10090788

ABSTRACT

Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SB 223412, hNK-3-CHO binding Ki = 1.4 nM) and 55 (3-NH2, hNK-3-CHO binding Ki = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 microM. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SB 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.


Subject(s)
Quinolines/chemical synthesis , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , CHO Cells , Calcium/metabolism , Cell Line , Cloning, Molecular , Cricetinae , Humans , In Vitro Techniques , Iris/drug effects , Iris/physiology , Mice , Miosis/physiopathology , Motor Activity/drug effects , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Peptide Fragments/pharmacology , Quinolines/chemistry , Quinolines/metabolism , Rabbits , Radioligand Assay , Receptors, Neurokinin-3/biosynthesis , Structure-Activity Relationship , Substance P/analogs & derivatives , Substance P/pharmacology
10.
J Pharmacol Exp Ther ; 281(3): 1303-11, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9190866

ABSTRACT

The in vitro and in vivo pharmacological profile of SB 223412 [(S)-(-)-N-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carbo xamide], a novel human NK-3 (hNK-3) receptor antagonist, is described. SB 223412 demonstrated enantioselective affinity for inhibition of [125I][MePhe7]neurokinin B (NKB) binding to membranes of CHO cells expressing the hNK-3 receptor (CHO hNK-3). SB 223412, the (S)-isomer, (Ki = 1.0 nM), has similar affinity as the natural ligand, NKB (Ki = 0.8 nM) and another nonpeptide NK-3 receptor antagonist, SR 142801 (Ki = 1.2 nM). SB 223412 was selective for hNK-3 receptors compared with hNK-1 (>10,000-fold selective) and hNK-2 receptors (>140-fold selective), and selectivity was further demonstrated by its lack of effect, in concentrations up to 1 or 10 microM, in >60 receptor, enzyme and ion channel assays. SB 223412 enantioselectively inhibited the NKB-induced Ca++ mobilization in HEK 293 cells stably expressing the hNK-3 receptor. SB 223412 (10-1,000 nM) produced concentration-dependent rightward shifts in NKB-induced Ca++ mobilization concentration-response curves with a Kb value of 3 nM. In addition, SB 223412 antagonized senktide-induced contraction in the isolated rabbit iris sphincter muscle (Kb = 1.6 nM). In mice, oral administration of SB 223412 produced dose-dependent inhibition of behavioral responses induced by the NK-3 receptor-selective agonist, senktide (ED50 = 12.2 mg/kg). Pharmacokinetic evaluation of SB 223412 in rat and dog indicated low plasma clearance, oral bioavailability and high and sustained plasma concentrations after 4 to 8 mg/kg oral dosages. The preclinical profile of SB 223412 (high affinity, selectivity, reversibility and oral activity) suggests that it will be a useful tool compound to define the physiological and pathophysiological roles of NK-3 receptors.


Subject(s)
Piperidines/pharmacology , Quinolines/pharmacology , Receptors, Neurokinin-3/drug effects , Receptors, Tachykinin/antagonists & inhibitors , Animals , CHO Cells/drug effects , Calcium/metabolism , Cricetinae , Dogs , Humans , Mice , Piperidines/pharmacokinetics , Rabbits , Radioligand Assay , Rats
11.
J Med Chem ; 40(12): 1794-807, 1997 Jun 06.
Article in English | MEDLINE | ID: mdl-9191956

ABSTRACT

A novel class of potent and selective non-peptide neurokinin-3 (NK-3) receptor antagonists, featuring the 4-quinolinecarboxamide framework, has been designed based upon chemically diverse NK-1 receptor antagonists. The novel compounds 33-76, prompted by chemical modifications of the prototype 4, have been characterized by binding analysis using a membrane preparation of chinese hamster ovary (CHO) cells expressing the human neurokinin-3 receptors (hNK-3-CHO), and clear structure-activity relationships (SARs) have been established. From SARs, (R)-N-[alpha-(methoxycarbonyl)benzyl]-2-phenylquinoline-4-carboxamide (65, SB 218795, hNK-3-CHO binding Ki = 13 nM) emerged as one of the most potent compounds of this novel class. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 65 is about 90-fold selective for hNK-3 versus hNK-2 receptors (hNK-2-CHO binding Ki = 1221 nM) and over 7000-fold selective versus hNK-1 receptors (hNK-1-CHO binding Ki = > 100 microM). In vitro functional studies in rabbit isolated iris sphincter muscle preparation demonstrated that 65 is a competitive antagonist of the contractile response induced by the potent and selective NK-3 receptor agonist senktide with a Kb = 43 nM. Overall, the data indicate that 65 is a potent and selective hNK-3 receptor antagonist and a useful lead for further chemical optimization.


Subject(s)
Quinolines/chemical synthesis , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , Binding, Competitive , CHO Cells , Chemical Phenomena , Chemistry, Physical , Cricetinae , Humans , Hydrogen Bonding , Molecular Structure , Muscle Contraction/drug effects , Peptide Fragments/pharmacology , Quinolines/metabolism , Rabbits , Receptors, Neurokinin-3/genetics , Receptors, Neurokinin-3/metabolism , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship , Substance P/analogs & derivatives , Substance P/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...